HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU | Zendy

Jun Sun | Zendy; Wei Wu | Zendy; Xiaofeng Tang | Zendy; Feifei Zhang | Zendy; Cheng Ju | Zendy; Renfeng Liu | Zendy; Yiping Liang | Zendy; Bo Yu | Zendy; Bin Lv | Zendy; Yuhong Guo | Zendy; Duo Zeng | Zendy; Xuchang Tao | Zendy; Min Wang | Zendy; Zhiping Zhang | Zendy; Changhua Zhang | Zendy; Xiaobin Lv | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU

Author(s) -

Jun Sun,

Wei Wu,

Xiaofeng Tang,

Feifei Zhang,

Cheng Ju,

Renfeng Liu,

Yiping Liang,

Bo Yu,

Bin Lv,

Yuhong Guo,

Duo Zeng,

Xuchang Tao,

Min Wang,

Zhiping Zhang,

Changhua Zhang,

Xiaobin Lv

Publication year - 2021

Publication title -

bioscience reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.938

H-Index - 77

eISSN - 1573-4935

pISSN - 0144-8463

DOI - 10.1042/bsr20203905

Subject(s) - osteosarcoma , pten , apoptosis , cancer research , in vivo , flow cytometry , chemistry , cell growth , protein kinase b , mtt assay , in vitro , biology , microbiology and biotechnology , pi3k/akt/mtor pathway , biochemistry

WT161, as a selective HDAC6 inhibitor, has been shown to play anti-tumor effects on several kinds of cancers. The aim of the present study is to explore the roles of WT161 in osteosarcoma and its underlying mechanisms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research